A phase I trial by the same team demonstrated that eight infusions of HER2Bi-armed ATC, in combination with low dose IL-2 and granulocyte-macrophage colony-stimulating factor, induced anti-tumor responses and increases in Th1 cytokines and IL-12 serum levels, without dose-limiting toxicities, in patients with HER2-positive and negative BC (33). The gene discussed is IL2; the disease is breast cancer.